18518183. METHODS AND MATERIALS FOR USING BIOMARKERS WHICH PREDICT SUSCEPTIBILITY TO CLOSTRIDIUM DIFFICILE INFECTION simplified abstract (Mayo Foundation for Medical Education and Research)
Contents
- 1 METHODS AND MATERIALS FOR USING BIOMARKERS WHICH PREDICT SUSCEPTIBILITY TO CLOSTRIDIUM DIFFICILE INFECTION
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 METHODS AND MATERIALS FOR USING BIOMARKERS WHICH PREDICT SUSCEPTIBILITY TO CLOSTRIDIUM DIFFICILE INFECTION - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.9.1 Unanswered Questions
- 1.9.2 How can the compositions mentioned in the patent application be optimized for maximum effectiveness in restoring healthy gut microbiota and treating CDI?
- 1.9.3 What are the potential long-term effects of using probiotics or fecal microbiota transplant to restore healthy gut microbiota in patients with CDI?
- 1.10 Original Abstract Submitted
METHODS AND MATERIALS FOR USING BIOMARKERS WHICH PREDICT SUSCEPTIBILITY TO CLOSTRIDIUM DIFFICILE INFECTION
Organization Name
Mayo Foundation for Medical Education and Research
Inventor(s)
Purna C. Kashyap of Rochester MN (US)
Eric J. Battaglioli of Rochester MN (US)
Vanessa L. Hale of Rochester MN (US)
METHODS AND MATERIALS FOR USING BIOMARKERS WHICH PREDICT SUSCEPTIBILITY TO CLOSTRIDIUM DIFFICILE INFECTION - A simplified explanation of the abstract
This abstract first appeared for US patent application 18518183 titled 'METHODS AND MATERIALS FOR USING BIOMARKERS WHICH PREDICT SUSCEPTIBILITY TO CLOSTRIDIUM DIFFICILE INFECTION
Simplified Explanation
The document discusses biomarkers of gut microbiota dysbiosis, focusing on bacteria that are altered in patients with diarrhea and/or susceptibility to infection (CDI). Compositions containing specific bacteria decreased in dysbiosis are also mentioned for potential treatment.
- Bacteria altered in gut microbiota dysbiosis can be used as biomarkers to predict dysbiosis in patients with diarrhea and/or susceptibility to infection (CDI).
- Compositions including at least three bacteria decreased in gut microbiota dysbiosis can be used to restore healthy gut microbiota, potentially through probiotics or fecal microbiota transplant, to treat CDI.
Potential Applications
The technology described in the patent application could be applied in: - Predicting gut microbiota dysbiosis in patients with diarrhea and/or susceptibility to infection. - Developing compositions to restore healthy gut microbiota and treat CDI.
Problems Solved
- Identifying biomarkers for gut microbiota dysbiosis. - Providing potential treatment options for CDI by restoring healthy gut microbiota.
Benefits
- Early detection and prediction of gut microbiota dysbiosis. - Potential non-antibiotic treatment options for CDI.
Potential Commercial Applications
"Predictive Biomarkers for Gut Microbiota Dysbiosis in CDI Treatment"
Possible Prior Art
There may be prior art related to the identification of specific bacteria as biomarkers for gut microbiota dysbiosis and their potential use in treating CDI.
Unanswered Questions
How can the compositions mentioned in the patent application be optimized for maximum effectiveness in restoring healthy gut microbiota and treating CDI?
Further research and clinical trials may be needed to determine the optimal formulation and delivery method for these compositions.
What are the potential long-term effects of using probiotics or fecal microbiota transplant to restore healthy gut microbiota in patients with CDI?
Long-term studies are necessary to assess the safety and efficacy of these treatments over extended periods.
Original Abstract Submitted
This document relates to biomarkers of gut microbiota dysbiosis. Bacteria that are increased or decreased in gut microbiota dysbiosis can be used as biomarkers to predict dysbiosis in patients with diarrhea and/or to predict susceptibility to infection (CDI). In addition, provided herein are compositions including at least three bacteria that are decreased in gut microbiota dysbiosis which can be used, for example, to restore heathy gut microbiota (e.g., by probiotic or by fecal microbiota transplant) to treat CDI.
